Is long-term administration of PLD-pegylated liposomal doxorubicin able to induce oral cancer?
Apoptosis
; 2024 Sep 06.
Article
in En
| MEDLINE
| ID: mdl-39242475
ABSTRACT
Leukoplakia, a potentially malignant oral condition, manifests as a nonremovable white lesion that is often linked to risk factors such as smoking, alcohol, and HPV. Pegylated liposomal doxorubicin (PLD), which is used in cancer treatment, has been associated with secondary oral cancers, particularly in patients with leukoplakia. A case study revealed the development of squamous cell carcinoma (SCC) on the tongue following PLD treatment, suggesting a potential link between the drug and malignant transformation. Despite the benefits of PLD in reducing cardiac toxicity, long-term oral monitoring is essential due to the persistent risk of oral cancer posttreatment.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Apoptosis
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: